LBPS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jan 1970 @ 01:00):

Stats
Dagens volum	3 914.00
Gjennomsnittsvolum	11 314.00
Markedsverdi	0.00
EPS	$0 ( 2022-03-31 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.220 (13.33%)

Volum Korrelasjon

Lang: 0.32 (neutral)

Kort: -0.32 (neutral)

Signal:(22.657) Neutral

4D pharma plc Korrelasjon

10 Mest positive korrelasjoner
UTHR	0.931
GOOD	0.925
ALXO	0.917
HALO	0.917
BEAT	0.917
BCYC	0.916
CBNK	0.915
PSHG	0.914
EAR	0.91
IBRX	0.908

10 Mest negative korrelasjoner
DAKT	-0.934
AXON	-0.914
DUOL	-0.912
LMNR	-0.908
DAIO	-0.901
OSPN	-0.901
BWMX	-0.9
ALTR	-0.899
OMAB	-0.897
ANSS	-0.897

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

4D pharma plc Korrelasjon - Valuta/Råvare

0.08
( neutral )

0.18
( neutral )

0.00
( neutral )

0.33
( neutral )

-0.29
( neutral )

-0.22
( neutral )

4D pharma plc Økonomi

Annual	2021
Omsetning:	$718 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.520

FY	2021
Omsetning:	$718 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.520

FY	2020
Omsetning:	$534 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.824

FY	2019
Omsetning:	$211 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.94

Financial Reports:

No articles found.

4D pharma plc

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.